Delayed onset, Long-term Efficacy of S-1 Monotherapy for an Elderly Patient with Squamous Cell Lung CancerNobuhiro Kanaji1*, Nobuki Nanki2, Akira Tadokoro1and Shuji Bandoh1
- *Corresponding Author:
- Nobuhiro Kanaji, MD, PhD
Department of Internal Medicine, Division of Hematology
Rheumatology and Respiratory Medicine
Faculty of Medicine, Kagawa University
1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
E-mail: [email protected]
Received date: October 22, 2014; Accepted date: November 23, 2014; Published date: December 5, 2014
Citation: Nobuhiro Kanaji, Nobuki Nanki (2014) Delayed onset, Long-term Efficacy of S-1 Monotherapy for an Elderly Patient with Squamous Cell Lung Cancer. Chemotherapy 3:139. doi:10.4172/2167-7700.1000139
Copyright: ©2014 Kanaji N, et al. This is an open-access article distributed under the terms of the Creativ Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The efficacy of S-1 monotherapy as a 2nd-line regimen for elderly patients with non-small cell lung cancer (NSCLC) has not been reported, nor has delayed onset regression after temporary progression of tumor during an identified therapeutic regimen. Here we report a 78-year-old man was diagnosed with T3N3M1b (BRA), stage IV squamous cell lung cancer. His primary lesion progressed after whole brain irradiation and 4 cycles of 1st-line chemotherapy with docetaxel. S-1 monotherapy was prescribed as the 2nd-line treatment. Each cycle of chemotherapy comprised 14 days of S-1 (40 mg, twice daily) followed by 14 drug-free days. After 6 months of S-1 monotherapy, primary and metastatic lesions had started regressing significantly. He continued S-1 monotherapy for 19 months (20 cycles) with a comfortable daily life until reaching progressive disease. S-1 monotherapy as a 2nd-line could be a therapeutic option for elderly patients with NSCLC. Moreover, long-term use of S-1 might be worth trying
if adverse events and tumor growth are tolerable and other anti-cancer drugs are not applicable, because S-1 has a potential for delayed onset efficacy.